Why Analysts See Significant Upside Potential for Intuitive Surgical

Intuitive Surgical (NASDAQ: ISRG) is currently navigating a challenging period, with its stock price retreating more than 30% from its 2025 highs. Despite this drawdown, Wall Street remains bullish on the medical robotics leader, with average price targets suggesting a potential recovery of over 30%. While the company’s price-to-earnings ratio of 51x may deter value-oriented investors, analysts argue that the underlying business fundamentals remain robust enough to justify this premium valuation.

The core of Intuitive Surgical’s strength lies in its recurring revenue model. While the company is famous for its da Vinci surgical systems, the majority of its income—roughly 75%—is derived from the sale of instruments, accessories, and services. This creates an annuity-like revenue stream that expands with every new system installation. With a 12% year-over-year increase in installed systems and a 17% rise in surgical procedures, the company continues to demonstrate strong market penetration and consistent demand for its robotic surgery ecosystem.

For investors, the current market volatility is not unprecedented. Historical data shows that Intuitive Surgical has weathered similar 30% drawdowns multiple times since its IPO, consistently recovering to reach new highs. Because the company’s business model is built on long-term service contracts rather than just one-time hardware sales, it is well-positioned to withstand temporary fluctuations in capital equipment spending. Consequently, for growth-focused investors, the current price dip may represent a strategic entry point into a company that maintains a dominant position in the evolving landscape of medical technology.